{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:09:06Z","timestamp":1780920546227,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Topical brepocitinib, a tyrosine kinase (TYK)2\/Janus kinase (JAK)1 inhibitor, is in development for psoriasis (PsO) and atopic dermatitis (AD). Quantitative analyses of prior clinical trial data were used to inform future clinical trial designs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Two phase 2b studies in patients with AD and PsO were used to characterize the amount of topical brepocitinib and the resultant systemic trough concentration (<jats:italic>C<\/jats:italic><jats:sub>Trough<\/jats:sub>) using a linear mixed-effects regression (LMER). This model was used to predict brepocitinib systemic <jats:italic>C<\/jats:italic><jats:sub>Trough<\/jats:sub> for higher treated body surface areas (BSAs) in adults and children. Information from non-clinical and clinical trials with oral brepocitinib was leveraged to set safety thresholds. This combined approach was used to inform future dose-strength selection and treated BSA limits.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Data from 256 patients were analyzed. Patient type, dose strength, and frequency had significant impacts on the dose\u2013exposure relationship. Systemic concentration in patients with PsO was predicted to be 45% lower than in patients with AD from the same dose. When topically applied to the same percentage BSA, brepocitinib systemic exposures are expected to be comparable between adults and children. The systemic steady-state exposure after 3% once daily and twice daily (2\u00a0mg\/cm<jats:sup>2<\/jats:sup>) cream applied to less than 50% BSA in patients with AD and PsO, respectively, maintains at least a threefold margin to non-clinical safety findings and clinical hematologic markers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The relationship between the amount of active drug applied and brepocitinib systemic <jats:italic>C<\/jats:italic><jats:sub>Trough<\/jats:sub>, described by LMER, may inform the development strategy for dose optimization in the brepocitinib topical program.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11095-024-03654-w","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T19:02:27Z","timestamp":1711134147000},"page":"623-636","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetic Profile of Brepocitinib with Topical Administration in Atopic Dermatitis and Psoriasis Populations: Strategy to Inform Clinical Trial Design in Adult and Pediatric Populations"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5119-6619","authenticated-orcid":false,"given":"Farzaneh","family":"Maleki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek S.","family":"Purohit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Nicholas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,22]]},"reference":[{"key":"3654_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jdin.2020.10.002","volume":"2","author":"K Urban","year":"2021","unstructured":"Urban K, Chu S, Giesey RL, Mehrmal S, Uppal P, Nedley N, Delost GR. The global, regional, and national burden of atopic dermatitis in 195 countries and territories: an ecological study from the Global Burden of Disease Study 2017. JAAD Int. 2021;2:12\u20138.","journal-title":"JAAD Int"},{"issue":"2","key":"3654_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/09546634.2020.1789050","volume":"33","author":"SG Danby","year":"2022","unstructured":"Danby SG, Draelos ZD, Gold LFS, Cha A, Vlahos B, Aikman L, Sanders P, Wu-Linhares D, Cork MJ. Vehicles for atopic dermatitis therapies: more than just a placebo. J Dermatolog Treat. 2022;33(2):685\u201398.","journal-title":"J Dermatolog Treat"},{"issue":"10","key":"3654_CR3","first-page":"108","volume":"6","author":"R Chovatiya","year":"2019","unstructured":"Chovatiya R, Silverberg JI. Pathophysiology of atopic dermatitis and psoriasis: implications for management in children. Children (Basel). 2019;6(10):108.","journal-title":"Children (Basel)"},{"issue":"8","key":"3654_CR4","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, Biswas P, Valdez H, DiBonaventura M, Nduaka C, Rojo R. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863\u201373.","journal-title":"JAMA Dermatol"},{"key":"3654_CR5","doi-asserted-by":"crossref","unstructured":"Mikhaylov D, Ungar B, Renert-Yuval Y, Guttman-Yassky E. Oral JAK inhibitors for atopic dermatitis. Ann Allergy Asthma Immunol. 2023:130(5):577\u201392.","DOI":"10.1016\/j.anai.2023.01.020"},{"issue":"5","key":"3654_CR6","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jaci.2011.01.053","volume":"127","author":"E Guttman-Yassky","year":"2011","unstructured":"Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis\u2013part I: clinical and pathologic concepts. J Allergy Clin Immunol. 2011;127(5):1110\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"4S","key":"3654_CR7","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","volume":"139","author":"PM Brunner","year":"2017","unstructured":"Brunner PM, Guttman-Yassky E, Leung DYM. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4S):S65\u201376.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"3654_CR8","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/bjd.14871","volume":"175","author":"R Bissonnette","year":"2016","unstructured":"Bissonnette R, Papp KA, Poulin Y, Gooderham M, Raman M, Mallbris L, Wang C, Purohit V, Mamolo C, Papacharalambous J, Ports WC. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016;175(5):902\u201311.","journal-title":"Br J Dermatol"},{"issue":"12","key":"3654_CR9","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","volume":"155","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, Zhu L, Papacharalambous J, Vincent MS, Peeva E. Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371\u20139.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"3654_CR10","first-page":"636","volume":"73","author":"KM Luba","year":"2006","unstructured":"Luba KM, Stulberg DL. Chronic plaque psoriasis. Am Fam Physician. 2006;73(4):636\u201344.","journal-title":"Am Fam Physician"},{"key":"3654_CR11","unstructured":"World Health Organization. Global report on psoriasis.\u00a026 October 2016. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789241565189."},{"key":"3654_CR12","doi-asserted-by":"crossref","unstructured":"EclinicalMedicine. The burden of psoriasis: a call for awareness. EClinicalMedicine. 2021;38:101114.","DOI":"10.1016\/j.eclinm.2021.101114"},{"issue":"5","key":"3654_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40257-013-0032-x","volume":"14","author":"W-H Boehncke","year":"2013","unstructured":"Boehncke W-H, Menter A. Burden of disease: psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2013;14(5):377\u201388.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"3654_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000062","volume":"2","author":"EJ Armstrong","year":"2013","unstructured":"Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2(2): e000062.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"3654_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1001\/2013.jamadermatol.406","volume":"149","author":"AW Armstrong","year":"2013","unstructured":"Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(1):84\u201391.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"3654_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/BOR.0000000000000147","volume":"27","author":"PJ Mease","year":"2015","unstructured":"Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol. 2015;27(2):127\u201333.","journal-title":"Curr Opin Rheumatol"},{"key":"3654_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2147\/ITT.S240891","volume":"10","author":"M Mosca","year":"2021","unstructured":"Mosca M, Hong J, Hadeler E, Hakimi M, Liao W, Bhutani T. The role of IL-17 cytokines in psoriasis. Immunotargets Ther. 2021;10:409\u201318.","journal-title":"Immunotargets Ther"},{"issue":"1","key":"3654_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13555-015-0092-3","volume":"6","author":"M Campa","year":"2016","unstructured":"Campa M, Mansouri B, Warren R, Menter A. A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol Ther (Heidelb). 2016;6(1):1\u201312.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"7","key":"3654_CR19","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.4049\/jimmunol.1400205","volume":"193","author":"MG Works","year":"2014","unstructured":"Works MG, Yin F, Yin CC, Yiu Y, Shew K, Tran TT, Dunlap N, Lam J, Mitchell T, Reader J, Stein PL, D\u2019Andrea A. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23\/IL-17 axis. J Immunol. 2014;193(7):3278\u201387.","journal-title":"J Immunol"},{"issue":"6","key":"3654_CR20","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/bjd.21826","volume":"187","author":"MN Landis","year":"2022","unstructured":"Landis MN, Arya M, Smith S, Draelos Z, Usdan L, Tarabar S, Pradhan V, Aggarwal S, Banfield C, Peeva E, Vincent MS, Sikirica V, Xenakis J, Beebe JS. Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging, and parallel-group study. Br J Dermatol. 2022;187(6):878\u201387.","journal-title":"Br J Dermatol"},{"key":"3654_CR21","doi-asserted-by":"crossref","unstructured":"Page KM, Suarez-Farinas M, Suprun M, Zhang W, Garcet S, Fuentes-Duculan J, Li X, Scaramozza M, Kieras E, Banfield C, Clark JD, Fensome A, Krueger JG, Peeva E. Molecular and cellular responses to the TYK2\/JAK1 inhibitor PF-06700841 reveal reduction of skin inflammation in plaque psoriasis. J Invest Dermatol. 2020;140(8):1546\u201355.e4.","DOI":"10.1016\/j.jid.2019.11.027"},{"issue":"2","key":"3654_CR22","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","volume":"85","author":"B King","year":"2021","unstructured":"King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, Zhu L, Cox LA, Craiglow B, Chen L, Banfield C, Page K, Zhang W, Vincent MS. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol. 2021;85(2):379\u201387.","journal-title":"J Am Acad Dermatol"},{"key":"3654_CR23","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Danese S, Leszczyszyn J, Romatowski J, Altintas E, Peeva E, Hassan-Zahraee M, Vincent MS, Reddy PS, Banfield C, Salganik M, Banerjee A, Gale JD, Hung KE. Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study. Clin Gastroenterol Hepatol. 2023:21(10):2616-2628.e7.","DOI":"10.1016\/j.cgh.2022.12.029"},{"key":"3654_CR24","unstructured":"Schaefer H, Redelmeier TE, Nohynek GJ, Lademann J. Chapter 215. Pharmacokinetics and Topical Applications of Drugs. In. Fitzpatrick\u2019s Dermatology in General Medicine, 8e. New York, NY: The McGraw-Hill Companies; 2012."},{"issue":"6","key":"3654_CR25","doi-asserted-by":"publisher","first-page":"5551","DOI":"10.18632\/aging.102946","volume":"12","author":"Z Wang","year":"2020","unstructured":"Wang Z, Man MQ, Li T, Elias PM, Mauro TM. Aging-associated alterations in epidermal function and their clinical significance. Aging (Albany NY). 2020;12(6):5551\u201365.","journal-title":"Aging (Albany NY)"},{"issue":"3","key":"3654_CR26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/bcp.12268","volume":"79","author":"HK Batchelor","year":"2015","unstructured":"Batchelor HK, Marriott JF. Formulations for children: problems and solutions. Br J Clin Pharmacol. 2015;79(3):405\u201318.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"3654_CR27","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/jcph.1360","volume":"59","author":"VS Purohit","year":"2019","unstructured":"Purohit VS, Ports WC, Wang C, Riley S. Systemic tofacitinib concentrations in adult patients with atopic dermatitis treated with 2% tofacitinib ointment and application to pediatric study planning. J Clin Pharmacol. 2019;59(6):811\u201320.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"3654_CR28","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1002\/jcph.1624","volume":"60","author":"V Purohit","year":"2020","unstructured":"Purohit V, Riley S, Tan H, Ports WC. Predictors of systemic exposure to topical crisaborole: a nonlinear regression analysis. J Clin Pharmacol. 2020;60(10):1344\u201354.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"3654_CR29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351.","journal-title":"AAPS J"},{"key":"3654_CR30","unstructured":"Antony F. MonolixSuite 2019R2. 30 January 2023. Available from: http:\/\/lixoft.com\/products\/monolix\/."},{"issue":"1","key":"3654_CR31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1214\/aos\/1018031103","volume":"27","author":"B Delyon","year":"1999","unstructured":"Delyon B, Lavielle M, Moulines E. Convergence of a stochastic approximation version of the EM algorithm. Ann Statist. 1999;27(1):94\u2013128.","journal-title":"Ann Statist"},{"key":"3654_CR32","unstructured":"R Core Team. R: a language and environment for statistical computing. In. Vienna: R Foundation for Statistical Computing; 2021."},{"issue":"12","key":"3654_CR33","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/cpdd.1163","volume":"11","author":"JH Hughes","year":"2022","unstructured":"Hughes JH, Qiu R, Banfield C, Dowty ME, Nicholas T. Population pharmacokinetics of oral brepocitinib in healthy volunteers and patients. Clin Pharmacol Drug Dev. 2022;11(12):1447\u201356.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"3654_CR34","unstructured":"Maleki F, Hughes J, Qiu R, Banfield C, Chang C, Purohit V, Peeva E, Beebe J, Wojciechowski J, Prybylski J, Nicholas T. Characterization of time-course of neutrophil after repeated oral administration of brepocitinib using a semi-mechanistic model. In. The 12th American Conference on Pharmacometrics (ACoP12); 2021."},{"issue":"24","key":"3654_CR35","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1200\/JCO.2002.02.140","volume":"20","author":"LE Friberg","year":"2002","unstructured":"Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol. 2002;20(24):4713\u201321.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3654_CR36","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1148\/radiol.2272012051","volume":"227","author":"J Eng","year":"2003","unstructured":"Eng J. Sample size estimation: how many individuals should be studied? Radiology. 2003;227(2):309\u201313.","journal-title":"Radiology"},{"issue":"4","key":"3654_CR37","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40257-021-00610-x","volume":"22","author":"X Gong","year":"2021","unstructured":"Gong X, Chen X, Kuligowski ME, Liu X, Cimino E, McGee R, Yeleswaram S. Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies. Am J Clin Dermatol. 2021;22(4):555\u201366.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"3654_CR38","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1365-2125.2006.02622.x","volume":"61","author":"I Mahmood","year":"2006","unstructured":"Mahmood I. Prediction of drug clearance in children from adults: a comparison of several allometric methods. Br J Clin Pharmacol. 2006;61(5):545\u201357.","journal-title":"Br J Clin Pharmacol"},{"key":"3654_CR39","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303\u201332.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"3654_CR40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3109\/15419061.2014.905930","volume":"21","author":"A Kobielak","year":"2014","unstructured":"Kobielak A, Boddupally K. Junctions and inflammation in the skin. Cell Commun Adhes. 2014;21(3):141\u20137.","journal-title":"Cell Commun Adhes"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-024-03654-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-024-03654-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-024-03654-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T15:09:23Z","timestamp":1713366563000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-024-03654-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,22]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["3654"],"URL":"https:\/\/doi.org\/10.1007\/s11095-024-03654-w","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,22]]},"assertion":[{"value":"26 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors are employees and shareholders of Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}